Aspirin use and colorectal cancer survival according to tumor CD274 (programmed cell death 1 ligand 1) expression status

Journal of Clinical Oncology

Volumn 35, Issue 16, 2017, Pages 1836-1844

  Hamada, Tsuyoshi ^a   Cao, Yin ^b,c   Qian, Zhi Rong ^a   Masugi, Yohei ^a   Nowak, Jonathan A ^a   Yang, Juhong ^a   Song, Mingyang ^b,c   Mima, Kosuke ^a   Kosumi, Keisuke ^a   Liu, Li ^a,c,e   Shi, Yan ^a,f   Silva, Annacarolina da ^a   Gu, Mancang ^a,g   Li, Wanwan ^a   Keum, NaNa ^c   Zhang, Xuehong ^a   Wu, Kana ^c   Meyerhardt, Jeffrey A ^a   Giovannucci, Edward L ^a,c   Giannakis, Marios ^a,d   Rodig, Scott J ^a   Freeman, Gordon J ^a   Nevo, Daniel ^c   Wang, Molin ^a,c   Chan, Andrew T ^a,b,d   Fuchs, Charles S ^a   Nishihara, Reiko ^a,c   Ogino, Shuji ^a,c   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^f Army General Hospital   (China)

^g ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; B RAF KINASE; CYCLOOXYGENASE 2; K RAS PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROGRAMMED DEATH 1 LIGAND 1; TRANSCRIPTION FACTOR CDX2; CD274 PROTEIN, HUMAN;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY MASS; CANCER DIAGNOSIS; CANCER SPECIFIC SURVIVAL; COHORT ANALYSIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG USE; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; UNITED STATES; BIOSYNTHESIS; COLORECTAL TUMOR; EPIDEMIOLOGY; IMMUNOLOGY; KAPLAN MEIER METHOD; MORTALITY; PROSPECTIVE STUDY;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGENS, CD274; ASPIRIN; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PROSPECTIVE STUDIES; UNITED STATES;

EID: 85021935139     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.70.7547     Document Type: Article

References (57)

1. Topalian SL, Drake CG, Pardoll DM: Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 27:450-461, 2015
2. Postow MA, Callahan MK, Wolchok JD: Immune checkpoint blockade in cancer therapy. J Clin Oncol 33:1974-1982, 2015
3. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
4. Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465, 2012
5. Le DT, Uram JN, Wang H, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509-2520, 2015
6. Xiao Y, Freeman GJ: The microsatellite in-stable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov 5:16-18, 2015
7. Li SK, Martin A: Mismatch repair and colon cancer: Mechanisms and therapies explored. Trends Mol Med 22:274-289, 2016
8. Llosa NJ, Cruise M, Tam A, et al: The vigorous immune microenvironment of microsatellite insta-ble colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 5:43-51, 2015
9. Gentles AJ, Newman AM, Liu CL, et al: The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 21: 938-945, 2015
10. Ogino S, Chan AT, Fuchs CS, et al: Molecular pathological epidemiology of colorectal neoplasia: An emerging transdisciplinary and interdisciplinary field. Gut 60:397-411, 2011
11. Colussi D, Brandi G, Bazzoli F, et al: Molecular pathways involved in colorectal cancer: Implications for disease behavior and prevention. Int J Mol Sci 14: 16365-16385, 2013
12. Guinney J, Dienstmann R, Wang X, et al: The consensus molecular subtypes of colorectal cancer. Nat Med 21:1350-1356, 2015
13. Phipps AI, Limburg PJ, Baron JA, et al: Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology 148:77-87.e72, 2015
14. Kuipers EJ, Grady WM, Lieberman D, et al: Colorectal cancer. Nat Rev Dis Primers 1:15065, 2015
15. Martinez-Useros J, Garcia-Foncillas J: Obesity and colorectal cancer: Molecular features of adipose tissue. J Transl Med 14:21, 2016
16. Chan AT, Ogino S, Fuchs CS: Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356:2131-2142, 2007
17. Chan AT, Ogino S, Fuchs CS: Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302:649-658, 2009
18. Rothwell PM, Wilson M, Elwin CE, et al: Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376:1741-1750, 2010
19. Liao X, Lochhead P, Nishihara R, et al: Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 367:1596-1606, 2012
20. Rothwell PM, Wilson M, Price JF, et al: Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials. Lancet 379:1591-1601, 2012
21. Li P, Wu H, Zhang H, et al: Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: A meta-analysis. Gut 64: 1419-1425, 2015
22. Domingo E, Church DN, Sieber O, et al: Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol 31: 4297-4305, 2013
23. Zelenay S, van der Veen AG, Böttcher JP, et al: Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162:1257-1270, 2015
24. Wang D, DuBois RN: The role of prostaglandin E(2) in tumor-associated immunosuppression. Trends Mol Med 22:1-3, 2016
25. Hutchinson L: Immunotherapy: Evading immune escape: Synergy of COX and immune-checkpoint inhibitors. Nat Rev Clin Oncol 12:622, 2015
26. Marzbani E, Inatsuka C, Lu H, et al: The invisible arm of immunity in common cancer chemo-prevention agents. Cancer Prev Res (Phila) 6: 764-773, 2013
27. Wu AA, Drake V, Huang HS, et al: Reprogramming the tumor microenvironment: Tumor-induced immunosuppressive factors paralyze T cells. OncoIm-munology 4:e1016700, 2015
28. Nishihara R, Wu K, Lochhead P, et al: Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 369:1095-1105, 2013
29. Ogino S, Nosho K, Irahara N, et al: Lym-phocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 15: 6412-6420, 2009
30. Yamauchi M, Morikawa T, Kuchiba A, et al: Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal color-ectum. Gut 61:847-854, 2012
31. Cao Y, Nishihara R, Wu K, et al: Population-wide impact of long-term use of aspirin and the risk for cancer. JAMA Oncol 2:762-769, 2016
32. Baba Y, Nosho K, Shima K, et al: Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res 15:4665-4673, 2009
33. Masugi Y, Nishihara R, Yang J, et al: Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut [epub ahead of print on May 5, 2016]
34. Ogino S, Nosho K, Kirkner GJ, et al: CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58: 90-96, 2009
35. Nosho K, Irahara N, Shima K, et al: Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 3:e3698, 2008
36. Ogino S, Nishihara R, VanderWeele TJ, et al: Review article: The role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology 27:602-611, 2016
37. Seaman SR, White IR: Review of inverse probability weighting for dealing with missing data. Stat Methods Med Res 22:278-295, 2013
38. Xie J, Liu C: Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. Stat Med 24:3089-3110, 2005
39. Zhang Y, Chen L: Classification of advanced human cancers based on Tumor Immunity in the MicroEnvironment (TIME) for cancer immunotherapy. JAMA Oncol 2:1403-1404, 2016
40. Sanmamed MF, Chen L: Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J 20:256-261, 2014
41. Dalerba P, Sahoo D, Paik S, et al: CDX2 as a prognostic biomarker in stage II and stage III colon cancer. N Engl J Med 374:211-222, 2016
42. Nosho K, Baba Y, Tanaka N, et al: Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: Cohort study and literature review. J Pathol 222:350-366, 2010
43. Ogino S, Galon J, Fuchs CS, et al: Cancer immunology–analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 8: 711-719, 2011
44. Di Caro G, Marchesi F, Laghi L, et al: Immune cells: Plastic players along colorectal cancer progression. J Cell Mol Med 17:1088-1095, 2013
45. Galon J, Mlecnik B, Bindea G, et al: Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol 232: 199-209, 2014
46. Rozek LS, Schmit SL, Greenson JK, et al: Tumor-infiltrating lymphocytes, Crohn’s-like lymphoid reaction, and survival from colorectal cancer. J Natl Cancer Inst 108:djw027, 2016
47. Mlecnik B, Bindea G, Angell HK, et al: Integrative analyses of colorectal cancer show immu-noscore is a stronger predictor of patient survival than microsatellite instability. Immunity 44:698-711, 2016
48. Prizment AE, Vierkant RA, Smyrk TC, et al: Cytotoxic T-cells and granzyme B associated with improved colorectal cancer survival in a prospective cohort of older women. Cancer Epidemiol Bio-markers Prev 10.1158/1055-9965.EPI-16-0641 [epub ahead of print on December 15, 2016]
49. Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, et al: PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol 29: 1104-1112, 2016
50. Inaguma S, Lasota J, Wang Z, et al: Clinico-pathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. Mod Pathol 30:278-285, 2017
51. Markosyan N, Chen EP, Evans RA, et al: Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity. Breast Cancer Res 15:R75, 2013
52. Göbel C, Breitenbuecher F, Kalkavan H, et al: Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity. Cell Death Dis 5:e1568, 2014
53. Javeed A, Zhang B, Qu Y, et al: The significantly enhanced frequency of functional CD4+CD25+Foxp3+ T regulatory cells in therapeutic dose aspirin-treated mice. Transpl Immunol 20:253-260, 2009
54. Sharma S, Stolina M, Yang SC, et al: Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 9:961-968, 2003
55. Stolina M, Sharma S, Lin Y, et al: Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164:361-370, 2000
56. Ogino S, Stampfer M: Lifestyle factors and microsatellite instability in colorectal cancer: The evolving field of molecular pathological epidemiology. J Natl Cancer Inst 102:365-367, 2010
57. Nishihara R, VanderWeele TJ, Shibuya K, et al: Molecular pathological epidemiology gives clues to paradoxical findings. Eur J Epidemiol 30:1129-1135, 2015